Chicago, IL (PRWEB) May 17, 2013
The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa of updated news on the site. A federal panel recently advised that the number of claims alleging internal bleeding has nearly tripled in the past few months*.
DrugRisk was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts have disagreed over whether it presents dangerous risks for internal bleeding. The FDA recently advised that Pradaxa is no more dangerous than traditional blood thinner warfarin**.
However, DrugRisk contains information from the Institute for Safe Medication Practices, who warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from Coumadin or warfarin. They also named anticoagulants like Pradaxa among the most dangerous drugs available***.
The resource center also contains a study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected****.
As of March 5, approximately 260 patients had filed a Pradaxa lawsuit alleging internal bleeding, resulting in cases being consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, DrugRisk has added a new report by the Judicial Panel on Multidistrict Litigation showing that the number of claims alleging internal bleeding has risen to 663 as of May 15, 2013*.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with their doctor or a lawyer about their legal options. However, due to the specialized nature of federal drug cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
*Judicial Panel on MultiDistrict Litigation 5/15/13; jpml.uscourts.gov/sites/jpml/files/Pending%20MDL%20Dockets_By%20District_May-14-2013.pdf
**FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834